Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19 DOI Creative Commons
Michela Murdocca, Osvaldo A. Santos‐Filho, Claudia De Masi

и другие.

Biology Direct, Год журнала: 2024, Номер 19(1)

Опубликована: Окт. 16, 2024

Язык: Английский

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency DOI Creative Commons
Lu Zhang,

Amy Kempf,

Inga Nehlmeier

и другие.

Cell, Год журнала: 2024, Номер 187(3), С. 596 - 608.e17

Опубликована: Янв. 8, 2024

Язык: Английский

Процитировано

78

Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity DOI Creative Commons

MST Monira Begum,

Kimiko Ichihara,

Otowa Takahashi

и другие.

Frontiers in Virology, Год журнала: 2024, Номер 4

Опубликована: Март 14, 2024

Introduction The severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike (S) protein is essential in mediating membrane fusion of the virus with target cells. Several reports demonstrated that SARS-CoV-2 S fusogenicity reportedly closely associated intrinsic pathogenicity determined using hamster models. However, association between and other virological parameters remains elusive. Methods In this study, we investigated (e.g., S1/S2 cleavage efficiency, plaque size, pseudoviral infectivity, pseudovirus entry viral replication kinetics) eleven previous variants concern (VOCs) interest (VOIs) correlating fusogenicity. Results discussion was found to be strongly correlated efficiency size formed by clinical isolates. less kinetics. Taken together, our results suggest could potential indicators predict newly emerged variants.

Язык: Английский

Процитировано

12

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification DOI Creative Commons
Laura E. Rosen, M. Alejandra Tortorici, Anna De Marco

и другие.

Cell, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing sufficiently potent clinical development and retain activity despite remain elusive. We identified human mAb, designated VIR-7229, which targets the receptor-binding motif (RBM) with unprecedented cross-reactivity all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently SARS-CoV-2 variants since 2019, recent EG.5, BA.2.86, JN.1. VIR-7229 tolerates extraordinary variability, partly attributed its high binding affinity, receptor molecular mimicry, interactions RBM backbone atoms. Consequently, features barrier selection of mutants, rare associated reduced fitness, underscoring potential be future evolution. is strong candidate become next-generation medicine.

Язык: Английский

Процитировано

8

Nonhuman primate antigenic cartography of SARS-CoV-2 DOI Creative Commons
Annika Rössler, Antonia Netzl, Ninaad Lasrado

и другие.

Cell Reports, Год журнала: 2025, Номер 44(1), С. 115140 - 115140

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

1

A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19 DOI
Daohong Zhang, Deepak Kukkar, Ki‐Hyun Kim

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 259, С. 129284 - 129284

Опубликована: Янв. 9, 2024

Язык: Английский

Процитировано

6

SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies DOI Creative Commons
Hailong Guo, Sha Ha, Jason Botten

и другие.

Viruses, Год журнала: 2024, Номер 16(5), С. 697 - 697

Опубликована: Апрель 28, 2024

Since the SARS-CoV-2 Omicron virus has gained dominance worldwide, its continual evolution with unpredictable mutations and patterns revoked all authorized immunotherapeutics. Rapid viral also necessitated several rounds of vaccine updates in order to provide adequate immune protection. It remains imperative understand how evolves into different subvariants causes escape as this could help reevaluate current intervention strategies mostly implemented clinics emergency measures counter pandemic and, importantly, develop new solutions. Here, we a review focusing on major events evolution, including features spike mutation that lead evasion against monoclonal antibody (mAb) therapy vaccination, suggest alternative durable options such ACE2-based experimental therapies superior mAbs address unprecedented virus. In addition, type unique virus-trapping molecules can zoonotic SARS coronaviruses, either from unknown animal hosts or established wild-life reservoirs SARS-CoV-2, even seasonal alpha coronavirus NL63 depends human ACE2 for infection.

Язык: Английский

Процитировано

6

Reverse mutational scanning of spike BA.2.86 identifies the epitopes contributing to immune escape from polyclonal sera DOI Creative Commons
Najat Bdeir,

Tatjana Lüddecke,

Henrike Maaß

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Янв. 3, 2024

ABSTRACT The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid mutations relative to BA.2. and its JN.1 derivative evade neutralization by serum antibodies of fully vaccinated individuals. In this study, we elucidate epitopes driving the immune escape via pseudovirus neutralization. Thus, have generated 33 mutants, each reverting a single mutation back We use library in an approach that call reverse mutational scanning define distinct titers against epitope. Mutations within receptor binding domain at K356T, V483Δ, lesser extent N460K, A484K, F486P enhance escape. Interestingly, 16insMPLF spike N-terminal P621S S1/S2 also significantly contribute antibody BA.2.86. Upon XBB.1.5 booster vaccination, improve considerably, residual is driven 16insMPLF, E554K, P621S, A484K. EDITOR’S SUMMARY SARS COV2 has over compared parental BA.2 lineage. Here Bdeir colleagues apply determine which among these present are linked from recognition.

Язык: Английский

Процитировано

5

Evolving spike-proteinN-glycosylation in SARS-CoV-2 variants DOI Creative Commons
Sabyasachi Baboo, Jolene K. Diedrich, Jonathan L. Torres

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Май 9, 2023

Since >3 years, SARS-CoV-2 has plunged humans into a colossal pandemic. Henceforth, multiple waves of infection have swept through the human population, led by variants that were able to partially evade acquired immunity. The co-evolution with immunity provides an excellent opportunity study interaction between viral pathogens and their hosts. heavily

Язык: Английский

Процитировано

11

Sarbecovirus RBD indels and specific residues dictating multi-species ACE2 adaptiveness DOI Creative Commons

Jun-Yu Si,

Yuanmei Chen,

Ye-Hui Sun

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Окт. 14, 2024

Our comprehensive understanding of the multi-species ACE2 adaptiveness sarbecoviruses remains elusive, particularly for those with various receptor binding motif (RBM) insertions/deletions (indels). Here, we analyzed RBM sequences from 268 categorized into four indel types. We examined ability 20 representative sarbecovirus Spike glycoproteins (S) and derivatives in utilizing bats several other mammalian species. reveal that long RBMs (type-I) can achieve broad tropism, whereas viruses single deletions Region 1 (type-II) or 2 (type-III) exhibit narrower tropism. Sarbecoviruses double region (type-IV) completely lost usage, which is restricted by clade-specific residues within outside RBM. Lastly, propose evolution indels illustrate how loop lengths, disulfide, residue determinants shape adaptiveness. This study provides profound insights mechanisms governing usage spillover risks sarbecoviruses.

Язык: Английский

Процитировано

4

Origin, evolution, and spread of SARS-CoV-2 DOI
Jonas Michel Wolf, Lucas Wolf,

Paul C. Wolf

и другие.

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 5 - 19

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0